Literature DB >> 9492110

A virilizing Leydig cell tumor of the ovary associated with stromal hyperplasia under gonadotropin control.

J A Marcondes1, M Nery, B B Mendonça, S A Hayashida, H W Halbe, F M Carvalho, B L Wajchenberg.   

Abstract

A 34-yr-old nulliparous black woman presented with hair loss, facial hirsutism, irregular menses and infertility associated with greatly increased serum total testosterone levels. The adrenal glands and the ovaries were normal on radiological and ultrasonographic investigation. Catheterization of the veins draining from the adrenal glands and the ovaries yielded testosterone levels of 20.3 nmol/L and 20.0 nmol/L in the right and the left adrenal veins, respectively, and 17.9 nmol/L and 27.4 nmol/L in the right and left ovaries venous plexus, respectively. Sequencial dexamethasone and ethynyl estradiol suppression test showed a decrease in cortisol level with no change in total testosterone level on dexamethasone while an increase in testosterone from 10.5 nmol/L to 20.1 nmol/L was observed ten days after ethynil estradiol had been associated to dexamethasone. When a gonadotropin-releasing hormone agonist (gonadorelin 3.5 mg i.m.) was administered for 2 months, serum gonadotropins levels decreased to less than 2 IU/L, total testosterone to 3.8 nmol/L and estradiol to less than 36 pmol/L. The patient was submitted to a pelvic exploratory laparotomy and a left salpingo-oophorectomy was performed. A solid and circumscribed ovarian tumor of 1.0 cm in diameter was found. The pathological diagnosis was a Leydig cell tumor with surrounding stromal hyperplasia. These findings may suggest that this tumor was gonadotropin-dependent being indirectly stimulated by ethynil estradiol, through a sensitization of the pituitary gonadotropes and increase in gonadotropin levels and suppressed by a gonadotropin-releasing hormone agonist.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9492110     DOI: 10.1007/BF03348033

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  9 in total

1.  Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist.

Authors:  K A Steingold; H L Judd; R K Nieberg; J K Lu; R J Chang
Journal:  Am J Obstet Gynecol       Date:  1986-06       Impact factor: 8.661

Review 2.  Clinical uses of luteinizing hormone-releasing hormone.

Authors:  S J Ory
Journal:  Fertil Steril       Date:  1983-05       Impact factor: 7.329

Review 3.  The polycystic ovary syndrome.

Authors:  S S Yen
Journal:  Clin Endocrinol (Oxf)       Date:  1980-02       Impact factor: 3.478

4.  Short term administration of gonadotropin-releasing hormone analog to a patient with a testosterone-secreting ovarian tumor.

Authors:  L Kennedy; A I Traub; A B Atkinson; B Sheridan
Journal:  J Clin Endocrinol Metab       Date:  1987-06       Impact factor: 5.958

5.  The effects of continuous androgen secretion on the hypothalamic-pituitary axis in woman: evidence from a luteinized thecoma of the ovary.

Authors:  A Dunaif; R E Scully; R N Andersen; D S Chapin; W F Crowley
Journal:  J Clin Endocrinol Metab       Date:  1984-09       Impact factor: 5.958

6.  Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.

Authors:  J A Marcondes; A C Abujamra; S L Minanni; B B Mendonca; M Nery; A C Lerario; M A Pereira; N Abelin; B L Wajchenberg
Journal:  Horm Metab Res       Date:  1993-02       Impact factor: 2.936

7.  Testosterone secretion by cultured arrhenoblastoma cells: suppression by a luteinizing hormone-releasing hormone agonist.

Authors:  S W Lamberts; J M Timmers; R Oosterom; T Verleun; F H de Jong
Journal:  J Clin Endocrinol Metab       Date:  1982-02       Impact factor: 5.958

8.  In vitro production of cyclic AMP and steroids from an ovarian Sertoli-Leydig cell tumor. Notes on clinical management.

Authors:  G Abrahamsson; E Dahlgren; M Hahlin; F Knutson; A Norström; P O Janson
Journal:  Acta Obstet Gynecol Scand       Date:  1995-04       Impact factor: 3.636

9.  The treatment of a hyperandrogenic and virilizing state in an elderly female with a synthetic LHRH agonist.

Authors:  J H Parr; R R Abraham; M Seed; F Short; V Wynn
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

  9 in total
  4 in total

Review 1.  Hirsutism: common clinical problem or index of serious disease?

Authors:  Oguz Tekin; Zekai Avci; Bünyamin Isik; Adem Ozkara; Cem Uraldi; Ferhat Catal; Elife Eraslan; Tuncay Delibasi
Journal:  MedGenMed       Date:  2004-10-15

2.  Severe hyperandrogenism due to ovarian hyperthecosis in a young woman.

Authors:  Alpesh Goyal; Rakhi Malhotra; Vidushi Kulshrestha; Garima Kachhawa
Journal:  BMJ Case Rep       Date:  2019-12-17

3.  Changing pattern of gonadotropins in a patient with an adrenal-androgen secreting tumor.

Authors:  Jose Antonio Miguel Marcondes; Cristiano R G Barcellos; Michelle P Rocha; Hélio Bisi
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 4.  Dynamic Testing for Evaluation of Adrenal and Gonadal Function in Pediatric and Adult Endocrinology: An Overview.

Authors:  Alpesh Goyal; Suraj Kubihal; Yashdeep Gupta; Viveka P Jyotsna; Rajesh Khadgawat
Journal:  Indian J Endocrinol Metab       Date:  2019 Nov-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.